U.S., Oct. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07217171) titled 'A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas' on Oct. 10.

Brief Summary: The goal of this study is to evaluate the safety and effectiveness of EVOLVE104 in participants with advanced urothelial and squamous cell carcinomas who have previously taken standard treatment options, have declined or have been ineligible for treatment with these medications. Participants with advanced or metastatic cancer who meet all eligibility criteria may be eligible to participate in the study.

Study Start Date: Oct. 15

Study Type: INTERVENTIONAL...